Siegfried: Management Changes
Siegfried Group (Zofingen) has announced two management changes. Chief Financial Officer (CFO) Michael Hüsler will be leaving the company at the end of April 2017 to take up a new professional challenge. Michael Hüsler has been CFO and a member of the firm’s Executive Committee since 2009. The Board of Directors has appointed Dr. Reto Suter, formerly CFO and Chief Investment Officer at Lonrho, as his successor. Reto Suter will take over the reins on May 1, 2017.
Says CEO Dr. Rudolf Hanko: “Michael Hüsler led the Finance department successfully and was instrumental in shaping and supporting our company’s expansion. He made a major personal contribution to Siegfried’s overall success during his tenure. We have found a highly experienced and competent successor to Michael Hüsler in Dr. Reto Suter.”
Likewise with effect from May 1, 2017, the Board of Directors has entrusted Dr. Wolfgang Wienand with the management of the Siegfried Group’s global research and development activities. He will be taking over these duties from Dr. René Imwinkelried and will perform this function in addition to his existing responsibilities as Head Strategy, M&A, Legal, IP and Regulatory Affairs. René Imwinkelried continues to manage the Global Technical Operations department – a role he has held since the beginning of the year.
As per May 1, 2017, the members of the Executive Committee are as follows:
- Dr. Rudolf Hanko, CEO
- Dr. Wolfgang Wienand, Head of Research and Development,
Head Strategy and M&A, Legal, IP, Regulatory Affairs - Dr. René Imwinkelried, Head of Global Operations
- Dr. Reto Suter, CFO
- Marianne Späne, Head Business Development & Sales
- Arnoud Middel, Head Human Re
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
OctoPlus announces positive Phase IIa efficacy and tolerability results for Locteron in hepatitis C
Cytori Reports Promising Results in Cell-Enriched Breast Reconstruction Trial

Mass Spectrometry and Interpreting Mass Spectra
Category:Medical_conditions_related_to_obesity
ClinTec’s CEO, Dr Rabinder Buttar wins the Institute of Directors, Director of the Year Award for Glasgow & West of Scotland

Shaping up the Genome for Cell Division - Researchers have uncovered the inner workings of the molecular machinery that shapes chromosomes during cell division

Candidalysin – the first toxin of Candida albicans - Team of German and British scientists discovers tissue-damaging fungal toxin

Wacker Chemie AG: Chemical and biotechnology divisions performed in a weak market environment in 2024 - Preliminary figures
